Overview
Status
Active
Registry date
2020-11-12
Share capital
5,000.00 PLN
Registered address
ul. Tadeusza Kościuszki 28/49, 30-105 Kraków, Poland
Electronic delivery address
AE:PL-79852-61819-HGITE-11
Financials
Revenue history
Filing timeliness
Financial statements were filed on time, on average 10 days early.
- 202509/07/2026
- 202415/07/2025
- 202311/07/2024
- 202229/06/2023
- 202122/06/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 6.65kMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD -7.84kMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 6.60kMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 26.56kMedianUSD 883.09kAverageUSD 31.39m
Industry
Authorized Representatives
Maciej Półtoranos – Liquidator
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Jacek Półtoranosage 39 | 20 | $270.12 | 20% |
Maciej Półtoranosage 68 | 60 | $810.37 | 60% |
Magda Skałaage 44 | 20 | $270.12 | 20% |
Maciej Półtoranos and Jacek Półtoranos hold a combined 80% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Organic Pharmasp. z o.o. | – | 23.6842% |
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 6, 2025 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | ||
| Fagronsp. z o.o. | $21,715,187.73 | fagron.pl | ||
| Krakowskie Zakłady Zielarskie Herbapol w KrakowieS.A. | $7,294,338.51 | herbapol.krakow.pl | ||
| F1 PharmaS.A. | $272,113.66 | f1pharma.pl | ||
| Ampliconsp. z o.o. | $48,330.99 | amplicon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Zakład Farmaceutyczny Amarasp. j. | $0.00 | amara.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-03-24 | Address change (Ul. Zamknięta 10/1.5, 30-554, Kraków → Ul. Tadeusza Kościuszki 28/49, 30-105, Kraków) | |
| 2025-02-20 | Name change (Ra-Pharm → Ra-Pharm Spółka Z Ograniczoną Odpowiedzialnością W Likwidacji) | |
| 2025-02-12 | Liquidation opened | |
| 2023-03-30 | Address change (Ul. Tadeusza Kościuszki 28/49, 30-105, Kraków → Ul. Zamknięta 10/1.5, 30-554, Kraków) | |
| 2020-11-12 | Entered in the register |
FAQ
The main business activity of Ra-Pharm focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on November 12, 2020.
The headquarters is located at: ul. Tadeusza Kościuszki 28, 30-105 Kraków.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $902 in 2024, which is a decrease of 52.6% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $6,144. For comparison, in 2023 the loss was $5,811, meaning the company increased its loss by 0.4%.
The largest operating cost category falls under other operating costs. This category amounted to $3,724 in 2024, representing 100% of all operating expenses.
Last updated: 2026-07-15